Focus on Lymphoma

 

Photo by Cancer Type

“Imbruvica’s approval demonstrates the FDA’s commitment to making treatments available to patients with rare diseases."

FDA Approves Imbruvica for Rare Blood Cancer

The U.S. Food and Drug Administration has approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. Imbruvica is intended for patients with MCL who have received at least one prior therapy. It works by inhibiting the enzyme needed by the cancer to multiply and spread. Imbruvica is the third drug approved to treat MCL. Velcade (2006) and Revlimid (2013) are also approved to treat the disease.

Read More

 

Photo by Cancer Type

Follow-Up Care for Non-Hodgkin Lymphoma

by Katherine L. Byar, MSN, APN, BC, and Julie M. Vose, MD

Improvements in therapy have in­creased survival rates for many people with non-Hodgkin lymphoma. How­ever, NHL survivors are still at risk for developing late complications after treatment ends. Routine follow-ups are needed to assess any long-term side effects of therapy and to check for signs of cancer recurrence.

Read More

 

Photo by Cancer Type

Cutaneous Lymphoma Founda­tion

by Susan Thornton

The Cutaneous Lymphoma Founda­tion, a nonprofit patient advocacy organization, strives to support each person with cutaneous lymphoma by promoting awareness and education, advancing patient care, and facilitating research. Cutaneous lymphoma is a rare form of non-Hodgkin lymphoma that develops in the skin.

Read More